NCT02911935View on ClinicalTrials.gov

Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Respiratory Syncytial Virus, Bronchiolitis
Interventions
DRUG

Oral azithromycin

Oral azithromycin 10mg/kg/day for 7 days; then oral azithromycin 5mg/kg/day for 7 additional days

DRUG

Placebo

Placebo suspension

Trial Locations (1)

63110

Department of Pediatrics, Washington University School of Medicine; and St. Louis Children's Hospital, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT02911935 - Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II | Biotech Hunter | Biotech Hunter